Paclitaxel
Showing 51 - 75 of 5,237
HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)
Not yet recruiting
- HR+/HER2- Breast Cancer
- (no location specified)
Nov 21, 2022
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 Trial
Not yet recruiting
- Metastatic Pancreatic Ductal Adenocarcinoma
- +3 more
- Biopsy
- +8 more
- (no location specified)
Jan 13, 2023
Solid Tumors Trial in United States (CORT125134 with nab-paclitaxel)
Completed
- Solid Tumors
- Relacorilant with nab-paclitaxel
-
Scottsdale, Arizona
- +3 more
Nov 9, 2022
Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8 Trial (drug, procedure,
Not yet recruiting
- Advanced Lung Non-Small Cell Carcinoma
- +3 more
- Carboplatin
- +9 more
- (no location specified)
Oct 21, 2023
Triple-Negative Breast Cancer Trial in Shanghai (Camrelizumab plus Famitinib with/without nab-Palitaxel)
Not yet recruiting
- Triple-Negative Breast Cancer
- Camrelizumab plus Famitinib with/without nab-Palitaxel
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center Shanghai, China, 200032
Jan 2, 2023
Head and Neck Squamous Cell Carcinoma, Oral Cancer Trial in Guangzhou (Tirelizumab ,+Carboplatin+albumin-bound paclitaxel)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Oral Cancer
- Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
-
Guangzhou, Guangdong, ChinaSun yat-sun memorial hospital
Jul 10, 2023
Head and Neck Squamous Cell Carcinoma Trial in United States (TAK-676, Carboplatin, 5-FU)
Completed
- Head and Neck Squamous Cell Carcinoma
- TAK-676
- +8 more
-
Shreveport, Louisiana
- +3 more
Oct 3, 2023
Switching H1-antagonist Clemastine to Cetirizine in
Active, not recruiting
- Solid Tumor
-
Rotterdam, Zuid-Holland, NetherlandsErasmus University Medical Center
Sep 8, 2023
Serum Interleukin-20 Level and Paclitaxel-associated Neuropathy
Recruiting
- Neuropathy Associated With Dysproteinaemias
- no intervention
-
Tekirdağ, TurkeyTekirdag Namik Kemal University
Nov 15, 2022
Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom
Active, not recruiting
- Triple Negative Metastatic Breast Cancer
- +3 more
- KU-0059436 (AZD2281)(PARP inhibitor)
- +3 more
-
Brussels, Belgium
- +3 more
Dec 19, 2022
Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)
Recruiting
- Her-2 Negative Breast Cancer
- HRR Gene Mutation
- Camrelizumab
- +2 more
-
Guangzhou, Guangdong, ChinaFirst Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023
Ovarian Cancer, Hyperthermic Intraperitoneal Chemo, Paclitaxel Trial in Guangzhou (Hyperthermic Intraperitoneal Paclitaxel
Recruiting
- Ovarian Cancer
- +2 more
- Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin
-
Guangzhou, Other (Non U.s.), ChinaSun Yat-sen Memorial Hospital
Nov 11, 2022
Metastatic Pancreatic Cancer Trial in Washington (Gemcitabine, Nab paclitaxel, Proglumide Dose level 1)
Not yet recruiting
- Metastatic Pancreatic Cancer
- Gemcitabine
- +3 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Apr 11, 2023
Breast - Female, Male Breast Cancer Trial in Charlotte (Pembrolizumab, Paclitaxel)
Completed
- Breast - Female
- Male Breast Cancer
- Pembrolizumab
- Paclitaxel
-
Charlotte, North CarolinaLevine Cancer Institute
Jan 25, 2023
Gastric Cancer, Peritoneal Metastases, Ascites, Malignant Trial in Hangzhou (Sintilimab in Combination With S-1/oxaliplatin With
Recruiting
- Gastric Cancer
- +2 more
- Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion
- Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 18, 2023
Locally Advanced Pancreatic Cancer Trial in Shanghai (Tumor treating fields combined with Gemcitabine HCl and albumin binding
Not yet recruiting
- Locally Advanced Pancreatic Cancer
- Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel
- Gemcitabine hydrochloride and albumin binding paclitaxel
-
Shanghai, Shanghai, ChinaHuashan Hospital Affiliated to Fudan University
Dec 8, 2022
Bladder Cancer Trial in Tianjin (Cadonilimab)
Recruiting
- Bladder Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Aug 23, 2023
Uterine Cervical Tumors, Cancer of Cervix, Cervical Cancer Trial (Cadonilimab, Nab paclitaxel)
Not yet recruiting
- Uterine Cervical Neoplasms
- +5 more
- Cadonilimab
- Nab paclitaxel
- (no location specified)
Apr 9, 2023
Pancreatic Cancer Trial in Boston, Philadelphia (Gemcitabine, Nab-paclitaxel, Paricalcitol)
Active, not recruiting
- Pancreatic Cancer
- Gemcitabine
- +3 more
-
Boston, Massachusetts
- +1 more
Jan 9, 2023
Resectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas Trial in Ulm (perioperative nab-paclitaxel/gemcitabine,
Completed
- Resectable Pancreatic Cancer
- Ductal Adenocarcinoma of the Pancreas
- perioperative nab-paclitaxel/gemcitabine
- adjuvant nab-paclitaxel/gemcitabine
-
Ulm, GermanyUniversity of Ulm, Dept. of Internal Medicine I
Nov 21, 2022
NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)
Recruiting
- Non-small Cell Lung Cancer
- Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
-
Wuhan, Hubei, ChinaUnion hospital
Feb 20, 2023
Ovarian Cancer Trial in Lexington (Lapatinib and Paclitaxel)
Recruiting
- Ovarian Cancer
- Lapatinib and Paclitaxel
-
Lexington, KentuckyMarkey Cancer Center
Dec 2, 2022